Fig. 3
From: CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer
A Kaplan‒Meier OS curves of GC patients with different HER2 levels in tumour tissues (log-rank test). B Kaplan‒Meier OS curves of GC patients with different PD-L1 levels in tumour tissues (log-rank test). C Differential expression of HER2 in tumour and paracancerous tissues of GC. D Differential expression of HER2 in tumour tissues and metastatic lymph nodes of GC. E The number of samples was based on expression of CLDN18.2 and HER2 in tumour tissues. F Differential expression of PD-L1 in tumour and paracancerous tissues of GC. G Differential expression of PD-L1 in tumour tissues and metastatic lymph nodes of GC. H The number of samples was based on expression of CLDN18.2 and PD-L1 in tumour tissues